Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2026-03-04 @ 11:10 PM
Study NCT ID:
NCT02131233
Status:
COMPLETED
Last Update Posted:
2019-01-30
First Post:
2014-05-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-05-23
Start Date Type:
ACTUAL
Primary Completion Date:
2015-12-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-12-19
Completion Date Type:
ACTUAL
First Submit Date:
2014-05-02
First Submit QC Date:
None
Study First Post Date:
2014-05-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-09-07
Results First Submit QC Date:
None
Results First Post Date:
2016-10-31
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-01-11
Last Update Post Date:
2019-01-30
Last Update Post Date Type:
ACTUAL